Mytocel MSKUnited Kingdom
Preparing a Rigeneracons RS device for the processing cycle

Clinic setup

From assessment to first case, in five decisions.

Actomed is the exclusive UK supplier of Mytocel MSK®, holding stock of Rigeneracons® RS and supporting N4SA installation.

Request a starter configurationTraining and support

Readiness

Designed for an established professional environment.

Clinical leadership

A named qualified clinician responsible for selection, consent, procedure and follow-up.

Appropriate environment

A setting able to support the required sterile field, consumables and professional workflow.

Governed adoption

Current documentation, training, stock control, outcome collection and incident reporting.

Gloved hands attaching a syringe to the single-use Rigeneracons RS device against a plain blue background.
Preparing the single-use device in a sterile field

Configuration

What Actomed will help you define.

  1. 01

    Reusable processing equipment

    The N4SA processing unit and compatible accessories required for the documented cycle.

  2. 02

    Single-use sterile devices

    Rigeneracons® RS stock aligned to planned clinic activity.

  3. 03

    Professional documentation

    Protocol, quick guide, FAQs and supporting clinical information.

  4. 04

    Training and first-case planning

    A route appropriate to your team, experience and intended service.

The N4SA processing unit photographed on a plain white background.
N4SA processing unit, the reusable unit in the configuration
The single-use Rigeneracons RS device photographed on a plain white background.
Rigeneracons RS, the single-use device reordered as a consumable

Governance and outcomes

Outcomes collected locally, records kept properly.

A gloved hand holding the sealed single-use cartridge in its pouch
Cartridges arrive sealed; protocol, records and consent sit with the clinic. Still from the manufacturer’s procedure video

Actomed provides KOOS and feedback templates for structured local outcome collection.

Patient selection, consent and follow-up remain with the treating clinician. The professional protocol states that signed consent and a clinical record are required.1

What would strengthen the evidence: a randomised comparison against hyaluronic acid or PRP, larger cohorts, standardised imaging. Actomed supports UK clinics collecting KOOS outcomes to contribute.

Territory

One supplier, two device markets.

Different device-market rules apply in Great Britain and Northern Ireland, so confirm the intended territory during the pricing and onboarding discussion.

Great Britain and Northern Ireland

Supply to Great Britain and Northern Ireland, with territory-specific conformity documentation.

CE marked; accepted on the Great Britain market under current transitional arrangements.

The adoption journey

Five steps from first discussion to ongoing supply.

  1. 01

    Professional discussion

    Clinical fit, evidence questions and clinic objectives.

  2. 02

    Pricing and configuration

    Reusable equipment, single-use devices and expected activity.

  3. 03

    Training and preparation

    Protocol training, equipment orientation, setup and supporting documentation.

  4. 04

    First-case pathway

    Agree practical first-case support and readiness before clinical use.

  5. 05

    Ongoing supply

    Consumables reordering, UK stock, product support and current resources.

References

  1. 1.Remedi (Regenera Activa). Mytocel MSK professional protocol. Manufacturer document. View source

Next step

Ready to define your configuration?

Tell Actomed about your clinic, team and expected activity. Current UK pricing and a starter configuration follow from that discussion.

Request UK pricingArrange an introduction